Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNT-OES-1 trial of FLOT followed by CROSS chemoradiotherapy in limited metastatic esophageal or gastroesophageal junction adenocarcinoma
NL-OMON49762Phase 2Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Dec 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid, oxaliplatin, docetaxel, carboplatin and 1 more in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma, sponsored by Erasmus MC. Primary endpoint: Feasibility of the combined regimens. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatindocetaxelcarboplatin
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON49762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49762.